Hsieh M, Nishizaki D, Adashek J, Kato S, Kurzrock R
Biomark Res. 2025; 13(1):32.
PMID: 39988665
PMC: 11849352.
DOI: 10.1186/s40364-025-00739-5.
Liu R, Liu Y, Huang W, Chen P, Cheng Y
Front Immunol. 2025; 16:1477913.
PMID: 39981252
PMC: 11839610.
DOI: 10.3389/fimmu.2025.1477913.
Haroun R, Naasri S, Oweida A
Vaccines (Basel). 2023; 11(4).
PMID: 37112730
PMC: 10146579.
DOI: 10.3390/vaccines11040818.
Wolpaw A, Grossmann L, Dessau J, Dong M, Aaron B, Brafford P
Proc Natl Acad Sci U S A. 2022; 119(6).
PMID: 35121657
PMC: 8832972.
DOI: 10.1073/pnas.2102358119.
Li A, Wu H, Tian Q, Zhang Y, Zhang Z, Zhang X
Front Oncol. 2021; 11:620200.
PMID: 34094905
PMC: 8173059.
DOI: 10.3389/fonc.2021.620200.
Roles of Toll-Like Receptor 3 in Human Tumors.
Zheng X, Li S, Yang H
Front Immunol. 2021; 12:667454.
PMID: 33986756
PMC: 8111175.
DOI: 10.3389/fimmu.2021.667454.
Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma.
Lomphithak T, Choksi S, Mutirangura A, Tohtong R, Tencomnao T, Usubuchi H
Cell Commun Signal. 2020; 18(1):161.
PMID: 33036630
PMC: 7545934.
DOI: 10.1186/s12964-020-00661-3.
Trial watch: TLR3 agonists in cancer therapy.
Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E
Oncoimmunology. 2020; 9(1):1771143.
PMID: 32934877
PMC: 7466857.
DOI: 10.1080/2162402X.2020.1771143.
Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients.
Bianchi F, Milione M, Casalini P, Centonze G, Le Noci V, Storti C
Sci Rep. 2019; 9(1):14288.
PMID: 31582772
PMC: 6776648.
DOI: 10.1038/s41598-019-50756-2.
Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation.
Kartikasari A, Prakash M, Cox M, Wilson K, C Boer J, Cauchi J
Front Immunol. 2019; 9:3109.
PMID: 30740111
PMC: 6357987.
DOI: 10.3389/fimmu.2018.03109.
Innate immune sensor laboratory of genetics and physiology 2 suppresses tumor cell growth and functions as a prognostic marker in neuroblastoma.
Lin L, Huang C, Wu M, Hsu W, Chuang J
Cancer Sci. 2018; 109(11):3494-3502.
PMID: 30179292
PMC: 6215871.
DOI: 10.1111/cas.13790.
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.
Nallasamy P, Chava S, Verma S, Mishra S, Gorantla S, Coulter D
Semin Cancer Biol. 2017; 52(Pt 2):53-65.
PMID: 29196189
PMC: 5972043.
DOI: 10.1016/j.semcancer.2017.11.009.
Exploiting poly(I:C) to induce cancer cell apoptosis.
Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L
Cancer Biol Ther. 2017; 18(10):747-756.
PMID: 28881163
PMC: 5678690.
DOI: 10.1080/15384047.2017.1373220.
Combinatorial treatment with polyI:C and anti-IL6 enhances apoptosis and suppresses metastasis of lung cancer cells.
Lau W, Zhu X, Ho S, Chang S, Ding J
Oncotarget. 2017; 8(20):32884-32904.
PMID: 28427199
PMC: 5464836.
DOI: 10.18632/oncotarget.15862.
Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.
Lin L, Huang C, Wu C, Wu M, Hsu W, Chuang J
Lab Invest. 2016; 96(7):719-30.
PMID: 27183205
DOI: 10.1038/labinvest.2016.57.
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
McCormick K, Ghosh A, Trivedi S, Wang L, Coyne C, Ferris R
Carcinogenesis. 2016; 37(5):522-9.
PMID: 26992898
PMC: 6086476.
DOI: 10.1093/carcin/bgw032.
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.
Guillerey C, Chow M, Miles K, Olver S, Sceneay J, Takeda K
Oncoimmunology. 2015; 4(9):e1027468.
PMID: 26405596
PMC: 4570135.
DOI: 10.1080/2162402X.2015.1027468.
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer.
Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I
Front Immunol. 2015; 6:402.
PMID: 26300886
PMC: 4528281.
DOI: 10.3389/fimmu.2015.00402.
MDA5 complements TLR3 in suppression of neuroblastoma.
Hsu W, Huang C, Lee H, Wu P, Wu M, Chuang H
Oncotarget. 2015; 6(28):24935-46.
PMID: 26208481
PMC: 4694805.
DOI: 10.18632/oncotarget.4511.